MDACC Study No:2012-0256 ( NCT No: NCT01621542)
Title:Initial Phase I Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies
Principal Investigator:Siqing Fu
Treatment Agent:WT2725
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of study drug WT2725 that can be given to patients with the following cancers:
acute myeloid leukemia, ovarian cancer, gilioblastoma, or non-small cell lung
cancer. The safety of WT2725 will also be studied.

WT2725 is a vaccine designed to help your immune system to fight against the
cancer cells by targeting a protein found in cancer cells called WT1, although
it is not known if it will do this. It is hoped that this may slow down the
growth of or kill cancer cells. This is the first study using WT2725 in
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Solid Tumors
Phase of Study:Phase I
Treatment Agents:WT2725
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sunovion Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Siqing Fu
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults